NIH | National Cancer Institute | NCI Wiki  

WIKI MAINTENANCE NOTICE

Please be advised that NCI Wiki will be undergoing maintenance Monday, July 22nd between 1700 ET and 1800 ET and will be unavailable during this period.
Please ensure all work is saved before said time.

If you have any questions or concerns, please contact the CBIIT Atlassian Management Team.

Versions Compared

Old Version 2

changes.mady.by.user Kuffel, Gina (NIH/NCI) [C]

Saved on

compared with

New Version 3

changes.mady.by.user Kuffel, Gina (NIH/NCI) [C]

Saved on

Key

  • This line was added.
  • This line was removed.
  • Formatting was changed.

...

Committee MemberPresentAbsent
Kuffel, Gina (NIH/NCI) [C]
X

Musk, Philip (NIH/NCI) [C]

X
Warren KibbeX
Kim, Erika (NIH/NCI) [E]
X
Gregory TawaX
William Hendriks
X
Matthew Breen
X
Roel VerhaakX



Goals

  • Review, discuss, and prioritize ICDC study submission proposals

...

Discussion ItemWhoNotes
New data submission request

Kuffel, Gina (NIH/NCI) [C] 

Data submission approved by Senior Advisory Committee

Kuffel, Gina (NIH/NCI) [C] 

  • "Immune Pathways and TP53 missense mutations are associated with longer survival in canine osteosarcoma" 
  • Data Submission Folder: OSA-Normal
  • Onboarding meeting set up with submitters
  • Study will be called OSA02
PRECINCT Data Request Submission: Inhaled IL-15 Immunotherapy for Treatment of Lung Metastases

All

  • PRECINCT SharePoint submission folder
  • PRECINCT Publication
  • Recently met with UC Davis team to demo the ICDC and discuss next steps for ingesting additional data.
Review of other Modiano publications: Other Modiano Publication Considerations.xlsx

Kuffel, Gina (NIH/NCI) [C]

Study Updates

Musk, Philip (NIH/NCI) [C]

  • TCL01
    • Study identifier changed to TCL01 (Tumor Cell Line)
    • Testing completed
    • Pending release record available on production
    • Still waiting on 6 study files being assembled
  • PRECINCT
    • Program now available on lower tier (dev environment)
    • Study record is in place
    • Working on Adverse Event node
    • Need follow-up call 
  • PANCAN01 (15 TB Re-analysis)
    • Data is already in a ICDC S3 bucket
    • Template-driven study onboarding initiated
    • One study will be onboarded at a time
    • Need to determine which study will be ingested first
  • OSA02
    • Onboarding meeting scheduled for Thursday

Minutes (Not Verbatim)

The meeting was cancelled and an email was sent instead to initiate a review of the newest data submission request.

Action items

**Discussion of Q&A email thread with data submitters of Tissue & Organoid study**

GT- Some science associated with cancer and IBD, evident link but not an expert in this area.

PM - The submission seems to be more about IBD than it is about cancer based on our discussion

RV - Is this a good fit for our data repo? Would sending it away prevent this data from ever being made accessible to the public?

RV - How many of the patient samples will ultimately have omics data associated with them?

WK - Struggling with the strong rationale to import this data. 

EK - Need metadata for the cancer related samples.

WK - Is there a place where these organoids can be validated and made available for other researchers?

GT - There are members of the SC that can help with depositing samples to and getting samples from, Christine Mazcko is our contact.

RV - The submission is beyond the scope of our resource, however we should help to make this data available.

GT - What is their plan is to have genomic coverage for all individuals?

WK - In favor of finding a way to accept.

EK - Potentially leverage resources from DCTD, looks like their grant involves drug development for bladder cancer.

WK - Moving into the drug screening space would be valuable.

Action items